Crossmark

A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)

Crossref DOI link: https://doi.org/10.1186/s13014-018-1096-9

Published Online: 2018-08-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mercier, Carole

Dirix, Piet https://orcid.org/0000-0002-1278-1903
Meijnders, Paul

Vermeulen, Peter

Van Laere, Steven

Debois, Hilde

Huget, Philippe

Verellen, Dirk
License Information

Text and Data Mining valid from 2018-08-20
More Information

Article History

Received: 7 June 2018

Accepted: 10 August 2018

First Online: 20 August 2018

Ethics approval and consent to participate

: The trial will be conducted in compliance with the principles of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013), the principles of good clinical practice and all of the applicable regulatory requirements. The study protocol received approval of the Ethics Committee of the GZA Hospitals, Belgium on 5th July 2017. Any subsequent protocol amendment will be submitted to the Ethics Committee for approval. CTO trial unit will conduct the trial and has ISO 9001 quality certificate since 18th April 2013. Informed consent from patients is mandatory before recruitment.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.